Stockwinners Market Radar for January 03, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:04 EST Cathie Wood's ARK Investment bought 105K shares of Tesla today

19:50 EST Aclarion Inc trading halted, news pending

19:36 EST Cloudflare director sells $765.8K in common stock - In a regulatory filing, Cloudflare disclosed that its director Carl Ledbetter sold 10K shares of common stock on January 3rd in a total transaction size of $765.8K.

18:36 EST FCA US reports Q4 U.S. sales fell 1% y/y - FCA US LLC reports sales of 343,552 vehicles in the fourth quarter and 1,527,090 vehicles for the full 2023 calendar year. Overall, fourth-quarter U.S. sales declined 1% while full-year results decreased 1%. Total U.S. sales within the company's commercial fleet channel increased 20% versus 2022, notching its best year ever. The company's total PHEV U.S. sales increased 124% year over year and 118% in the fourth quarter versus last year. FCA takes the 1-2-3 spots among best-selling plug-in hybrids in the U.S. The Jeep Wrangler 4xe is America's best-selling plug-in hybrid vehicle; the Grand Cherokee 4xe is No. 2 and the Chrysler Pacifica Hybrid claims the No. 3 spot. FCA US holds the highest PHEV market share in the industry, owning 47%. Stellantis is setting the course for 50% passenger-car and light-duty truck battery-electric vehicles (BEV) sales mix in the United States by the end of this decade.

17:48 EST Nordson EVP Lovass sells 2,000 common shares - In a regulatory filing, Nordson executive VP Stephen Lovass disclosed the sale of 2,000 common shares of the company on January 2 at a price $258.68 per share.

17:30 EST L3Harris Technologies awarded $479M USSOCOM contract - L3Harris Technologies was awarded a single award, indefinite-delivery/indefinite-quantity, firm-fixed-price contract, with seven one-year ordering periods, and a potential maximum value of $479M for the continued procurement of next generation tactical communications radios and associated sustainment and support services as required in support of U.S. Special Operations Command, or USSOCOM. FY24 procurement funds in the amount of $2.52M are being obligated at time of award. This contract shall result in delivery orders funded with valid procurement, operations, and maintenance funding, and research, development, testing, and evaluation funding as appropriate. This contract was awarded under the Competition in Contracting Act exception to full and open competition as implemented by Federal Acquisition Regulation 6.302-1. USSOCOM is the contracting activity.

17:16 EST Sky Harbour updates development budget for Dallas Addison Airport - Sky Harbour released an update to its development budget for Dallas Addison - ADS - Airport Phase 1, from an estimated range of $25M-$27M to an estimated range of $30M-$32M. The increase is largely due to owner-initiated improvements intended to enhance the quality and aesthetic of Sky Harbour's offering to residents and introduced as a result of learnings at existing Sky Harbour facilities. In Q1, the company intends to make cash contributions in the amount necessary to fund these estimated cost increases from unrestricted funds on hand at the corporate level into Sky Harbour Capital and the Obligated Group's construction fund.

17:05 EST CVS Caremark accelerates biosimilars adoption through formulary changes - CVS Caremark (CVS), a CVS Health company, announced the continuation of its efforts to expand adoption of biosimilars. Effective April 1 Humira will be removed from our major national commercial template formularies and Humira biosimilars will be covered. Humira will continue to be an option for its customers with Choice and Standard Opt Out commercial formularies. Commercial formularies are the drug lists used by employers, unions and health plans for prescription drug coverage. In much the same way that generic drugs are used as alternatives to branded drugs, biosimilars offer quality, safe, and effective treatment options that have no clinically meaningful difference from their reference products. A vibrant and competitive biosimilar market is essential to driving sustainable cost savings and options for consumers over the long term. The biosimilars market in the U.S. is projected to grow from less than $10B in 2022 to more than $100B by 2029. "We are committed to accelerating the adoption of biosimilars and providing customer choice alongside a seamless member experience," said David Joyner, Executive Vice President, CVS Health and President of CVS Caremark. "Our customers want to have choices. By preferring biosimilars that have a significantly lower list price than their reference product, CVS Caremark is putting our customers in the driver's seat to best meet the health care needs of their members and lower drug costs." The company also announced that AbbVie, (ABBV) as part of its continued commitment to access, has entered into an agreement to supply Cordavis, a CVS Health company, with a committed volume of co-branded Humira. This will provide another treatment option for adalimumab patients and aligns to the CVS Caremark focus on customer choice and seamless member experience. The Cordavis Humira product will be available in the second quarter. Cordavis Humira provides additional options for payors.

17:02 EST Aquaron Acquisition extends period to consummate business combination - Aquaron Acquisition announced that Bestpath IoT has deposited into the company's trust account an aggregate of $210K in order to extend the period of time the company has to complete a business combination for three additional months, from October 6, 2023 to January 6, 2024. The company issued a promissory note to Bestpath with a principal amount equal to the amount deposited. The promissory note bears no interest and is convertible into the company's shares of common stock at a price of $10.00 per unit at the closing of a business combination by the company. The purpose of the extension is to provide more time for the company to complete a business combination.

16:36 EST HP Inc. CEO Lores sells 38,000 common shares - In a regulatory filing, HP Inc. president and CEO Enrique Lores disclosed the sale of 38,000 common shares of the company on January 2 at a price of $29.75 per share.

16:35 EST Crane says Vian deal to be accretive to segment EBITDA margins immediately - CEO, Max Mitchell, said: "We are very excited to announce this transaction. Vian is highly complementary to our Fluid Solution within the Aerospace & Electronics segment, significantly expanding our portfolio of mission critical aerospace flow control products. Vian has strong positions on the most attractive commercial and military aircraft platforms today, and combined with our existing fluid and thermal management capabilities, further strengthens our positioning for future content opportunities on engines, gearboxes and auxiliary power units. We expect that Vian's margins will be accretive to the Aerospace & Electronics' segment EBITDA margins immediately, with a long-term sales growth rate in line with the segment's previously disclosed 7% to 9% long-term CAGR. Vian, along with the other acquisitions that we continue to pursue, meets our clearly defined strict financial and strategic acquisition criteria."

16:33 EST Canaan secures follow-on purchase orders from Cipher and Stronghold - Canaan (CAN) has secured follow-on purchase orders from joint venture entities of Cipher Mining (CIFR) and from Stronghold Digital Mining (SDIG). The orders, which combined involve the purchase of over 17,000 Bitcoin mining machines, build upon Canaan's existing relationships with Cipher and Stronghold. On December 29, 2023, Cipher entered into an agreement whereby two joint venture entities in which Cipher has a 49% interest purchased from Canaan 16,700 A1466 model mining machines with an average hash rate of 150T/s. These machines are to be delivered in April and May 2024 for use at Cipher's Bear and Chief data centers, both located in Texas. The 11,000 A1346 model mining machines which were purchased on May 9, 2023 have been delivered and installed at Cipher's Odessa data center. On December 26, Stronghold entered into an agreement whereby Stronghold has purchased from Canaan 1,100 A1346 model mining machines with an average hash rate of 123T/s. These are to be delivered by January 2024 for use at Stronghold's Scrubgrass Plant. Additionally, Stronghold has an option to purchase an additional 2,500 A1466 model mining machines with an average hash rate of 140T/s-150T/s. The 2,000 A1346 model mining machines which were purchased on July 27, 2023 have been delivered and installed at Stronghold's Patha Creek Plant.

16:33 EST Fenbo Holdings appoints Meng Derong as co-chairman - Fenbo Holdings announced the appointment of Meng Derong as co-chairman and independent non-executive director, effective on January 1. Meng has over 20 years of experience in enterprise management, particularly in operational management of supply chain systems.

16:30 EST Regional Management announces departure of COO John Schachtel - Regional Management "announced that Executive Vice President and COO John Schachtel is leaving Regional Management. Rob Beck, President and Chief Executive Officer, and other members of the executive team are expected to absorb Mr. Schachtel's responsibilities post-departure."

16:25 EST Summit Materials' pending Cementos Argos transaction recommended - Summit Materials announced that proxy advisory firms ISS and Glass Lewis have recommended that Summit shareholders vote in favor of all proposals in connection with its pending combination with Argos North America, the U.S. operations of Cementos Argos, at the company's upcoming Special Meeting of Stockholders on Thursday, January 11. In making their respective recommendations, ISS and Glass Lewis stated: "Support for the transaction is warranted in light of compelling strategic rationale and the expected financial benefits. The combined entity will have increased scale, a more diversified geographic presence, and the transaction is expected to result in significant cost savings and be accretive to free cash flow per share." "The deal should greatly enhance the company's scale and geographic reach, which could better position the company to take advantage of various anticipated tailwinds relating to the supply and demand for cement. The company also expects to realize at least $100M in annual run-rate cost synergies from the proposed transaction through various means, including operational efficiencies, optimizing sourcing and increased utilization of the import terminals' network." The transaction is expected to close in 1Q24, subject to customary closing conditions, including approval by Summit Materials shareholders.

16:21 EST Ellomay Capital to sell Talmei Yosef, Israel, solar facility for $12.2M - Ellomay Capital it executed an agreement to sell its holdings in the 9 MW solar facility located in Talmei Yosef, Israel. The agreement provides for the sale of the company's holdings in the Talmei Yosef Facility to Greenlight Fund and Doral Group Renewable Energy, in equal parts, in consideration for NIS 44.75M - approximately $12.2M, with an additional potential payment of up to NIS4M in the event the Talmei Yosef Facility will produce more than 18 million Kwh during 2024. The agreement provides for a cutoff date of June 30, 2023 and the company will be entitled to all revenues of the Talmei Yosef Facility up to such date, net of expenses for the period. The agreement includes customary representations and indemnification undertakings in connection with breaches of representations, which, other than with respect to customary exceptions, are subject to a cap of NIS9M and limited to a period of 18 months from the closing date. All conditions to closing are required to be fulfilled within a period of 90 days from execution of the Agreement, which can be extended to up to 150 days under certain circumstances. One of the conditions to closing is the end of the war in southern Israel and that the Talmei Yosef Facility will be physically accessible. In addition, the Agreement provides that in the event that due to the current war and hostilities in Israel the facility will be damaged or its output will decrease, the buyers will have the right not to consummate the acquisition of the facility. Following consummation of the sale, the company will maintain the rights to the two projects under development located in the vicinity of the Talmei Yosef Facility,

16:17 EST Cognex CFO Paul Todgham resigns - Cognex SVP, Finance and CFO Paul Todgham has resigned from his position effective March 15, 2024. Todgham will continue to serve in the role of CFO until March 15 and will remain available to the company on a consulting basis after that time. Cognex is conducting a search process to identify a new CFO.

16:17 EST Americold Realty Trust CFO Marc Smernoff to depart, Jay Wells to succeed - Americold Realty Trust (COLD) announced a series of leadership updates. As part of these changes, the company and Marc Smernoff, executive VP and CFO, have mutually agreed that Smernoff's employment with the company will terminate, effective January 12. Jay Wells has been appointed to succeed Smernoff as executive VP and CFO, effective January 15. Wells joins Americold from Primo Water (PRMW). ,

16:16 EST Cal-Maine Foods falls 5% to $51.91 after Q2 earnings miss

16:12 EST Cal-Maine Foods CFO says decline in Q2 revenue due to lower egg selling prices - CFO Max Bowman states: ""For the second quarter of fiscal 2024, our net sales were $523.2 million compared with $801.7 million for the same period last year. The decline in sales revenue for the second quarter of fiscal 2024 was primarily due to the significant decrease in the net average selling price for conventional eggs. However, our sales volumes improved slightly with 288.2 million total dozens sold in the second quarter of fiscal 2024 compared with 284.1 million, an increase of 1.4%, over the same period last year. Net income attributable to Cal-Maine Foods, Inc. for the second quarter of fiscal 2024 was $17.0 million, or $0.35 per diluted share, compared with $198.6 million, or $4.07 per diluted share, for the second quarter of fiscal 2023. These results include a $19.6 million loss contingency accrual, reflected in SG&A expenses, for our estimated share of damages and fees awarded in a pending anti-trust legal proceeding. We are still pursuing legal actions to reverse, and if necessary, appeal the decisions. While conventional egg prices improved sequentially, the net average selling price per dozen was $1.458 for conventional eggs in the second quarter of fiscal 2024, down 49.4% compared with $2.883 for the prior-year quarter. Net average selling price for specialty eggs was $2.277 per dozen, compared with $2.370 per dozen for the second quarter of fiscal 2023, a decline of 3.9%. Specialty dozens sold were 33.2% of total dozens sold in the second quarter of fiscal 2024 compared with 33.8% in the prior-year period. Cage-free eggs accounted for approximately 30.4% of shell egg revenue for the second quarter of fiscal 2024. We reported operating income of $14.2 million for the second quarter of fiscal 2024, compared with operating income of $259.9 million for the prior-year quarter, primarily reflecting lower market prices. However, we benefitted from lower feed ingredient prices compared with the same period a year ago. We continued to focus on the aspects of our business we can control and managed our operations efficiently despite higher input costs at our production, processing and distribution centers, as well as ongoing investments in enhanced biosecurity measures to mitigate the risk of highly pathogenic avian influenza".

16:09 EST Simulations Plus names Will Frederick COO, Dan Szot CRO - Simulations Plus announced the following leadership changes effective January 3, 2024. "We are excited to announce key strategic appointments that will advance our objective to seamlessly and organically align with our clients' needs," said Shawn O'Connor, Chief Executive Officer. "We have a deep bench of talent at Simulations Plus, and I am delighted to recognize the excellent leadership and accomplishments that each person has demonstrated. This team has a wide range of experience, proven execution and a shared vision that will strengthen our ability to realize our strategic growth initiatives." Will Frederick, currently Chief Financial Officer, assumes the additional role of Chief Operating Officer in recognition of his operational leadership. Mr. Frederick has served as Chief Financial Officer since joining Simulations Plus in December 2020. Dan Szot joins Simulations Plus as Chief Revenue Officer. In this new role, Mr. Szot oversees the sales and marketing teams to identify collaborative cross-selling opportunities and enhance productivity. Mr. Szot was previously at Dassault Systemes where he served as Global Vice President of Sales and Field Operations for the BIOVIA brand. In his over 20 years in the industry, Mr. Szot has had broad experience across all phases of drug development in large organizations in enterprise sales, research discovery, and clinical applications. Mr. Szot reports to Shawn O'Connor, Chief Executive Officer. Josh Fohey transitions from Vice President of Business Development to Senior Vice President, Operations. In this key operational role, Mr. Fohey will leverage his customer insights to provide leadership across all business units supporting client-focused services operations, product operations, and quality management. Mr. Fohey joined Simulations Plus in 2019 as Director of Operations and was promoted to Vice President, Operations in 2020. Prior to joining Simulations Plus, he had several operational, scientific, and business development roles during his 14 years at Covance. In his new role, Mr. Fohey reports to Will Frederick, Chief Financial Officer and Chief Operating Officer. Sandra Suarez-Sharp, Ph.D., currently Vice President, Regulatory Affairs, is promoted to President, Regulatory Strategies.

16:06 EST Foghorn Therapeutics CFO Allan Reine to depart - Foghorn Therapeutics announced that CFO, Allan Reine will be departing the company to pursue another opportunity. The company has commenced a formal search for a successor. Reine's last day as a full-time employee with Foghorn will be January 16.

16:05 EST Intel names Justin Hotard to lead Data Center and AI Group - Intel Corporation announced the appointment of Justin Hotard as executive vice president and general manager of its Data Center and AI Group, effective Feb. 1. He joins Intel with more than 20 years of experience driving transformation and growth in computing and data center businesses, and is a leader in delivering scalable AI systems for the enterprise. Hotard will become a member of Intel's executive leadership team and report directly to CEO Pat Gelsinger. He will be responsible for Intel's suite of data center products spanning enterprise and cloud, including its Intel(R) Xeon(R) processor family, graphics processing units and accelerators. He will also play an integral role in driving the company's mission to bring AI everywhere.

16:05 EST Cognex CFO to resign, company conducting search for new CFO - In a regulatory filing, Cognex disclosed that on January 3, the company and Paul Todgham, Senior Vice President of Finance and Chief Financial Officer of the company, mutually agreed that Mr. Todgham will resign from the company, effective March 15, 2024. "Mr. Todgham's resignation was not the result of any disagreements with the company on any matters relating to its operations, policies or practices. The company is conducting a search for a new Chief Financial Officer," Cognex stated.

16:04 EST BridGene in $27M collaboration and licensing pact with Galapagos - BridGene Biosciences announced a strategic collaboration and licensing agreement with Galapagos . Under the collaboration, BridGene will use its chemoproteomics platform, IMTAC , to discover novel small molecule drug candidates against the collaboration targets. The parties will collaborate to advance the molecules to clinical candidates, which Galapagos has the exclusive rights to develop and commercialize.The preclinical research collaboration will focus on oncology targets named by Galapagos. Galapagos will pay BridGene up to $27M in upfront and preclinical research milestone payments and more than $700M in clinical and commercial milestones, assuming success of the programs. BridGene is also eligible to receive tiered royalties on net sales of each product resulting from the collaboration. "BridGene's proven expertise in discovering small molecule drugs for challenging targets positions them as an ideal partner in pioneering new avenues in oncology drug discovery," said Pierre Raboisson, PhD, Senior Vice President and Head of Small Molecules Discovery at Galapagos. "By integrating BridGene's innovative platform with our robust capabilities in drug discovery and clinical development, we are poised to develop breakthrough cancer therapies. Our goal is to deliver transformative precision medicines for cancer with limited treatment options."

16:01 EST Hancock Whitney Bank president Joe Exnicios to retire March 1, 2024 - Senior Executive Vice President of Hancock Whitney Corporation and President of Hancock Whitney Bank Joseph S. "Joe" Exnicios has announced his planned retirement date of March 1, 2024. He has been with the company since 1978. "Joe Exnicios has been a driving force behind our organization's success as a financial and community partner throughout the metropolitan New Orleans region for the past 46 years," said Hancock Whitney President and Chief Executive Officer John Hairston. "Having been a bank leader in the New Orleans market early in his career, Joe transitioned to lead the commercial bank before assuming several executive positions, ultimately reaching the role of bank president. While Joe has enjoyed tremendous success as an executive, his greatest gift has been in coaching and mentoring hundreds of young bankers during his many years in service."

14:02 EST Pono Capital Three Inc trading resumes

13:44 EST TeraWulf self-mines 334 bitcoin in December - December 2023 Highlights: Self-mined 334 bitcoin in December with an average production rate of over 10 bitcoin per day. Power cost averaged $11,212 per bitcoin self-mined, or approximately $0.038/kWh in December. Building 3 at the Lake Mariner facility is operationally ready with energization of additional 18,500 S19j XP miners expected in February 2024. Construction of Building 4 is underway. Expansion of existing high-performance computing project supporting generative AI and large language model applications at the Lake Mariner facility, planned for 2024. Expect to repay approximately $14 million of debt with cash generated in Q4 2023, with an $11 million expected repayment in January 2024, thereby reducing the Company's future interest payments. "During December, the Company mined 334 bitcoin, a slight increase from November's bitcoin production, due to continued improvement leveraging lower winter temperatures across both the Lake Mariner and Nautilus facilities, along with streamlined miner maintenance and healthy transaction fees," said Sean Farrell, SVP of Operations at TeraWulf. "The Lake Mariner team also performed routine maintenance in December on the primary transformer that feeds approximately 4,700 miners. The 15-day outage included replacement of the tertiary bushings on the unit as a preventative measure to ensure long term reliability."

13:07 EST North American rail traffic up 4.4% for the week ending December 30 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending December 30, as well as volumes for December 2023. U.S. railroads originated 876,881 carloads in December 2023, up 7.3%, or 59,804 carloads, from December 2022. U.S. railroads also originated 982,383 containers and trailers in December 2023, up 10.2%, or 90,881 units, from the same month last year. Combined U.S. carload and intermodal originations in December 2023 were 1,859,264, up 8.8%, or 150,685 carloads and intermodal units from December 2022. "Total U.S. rail carloads were up 2.% in the fourth quarter of 2023 over the fourth quarter of 2022, while U.S. intermodal was up 5.5 % over the same period. That means Q4 was clearly the best quarter of 2023 for U.S. rail volumes on a year-over-year basis," said AAR Senior Vice President John T. Gray. "It appears that intense rail efforts to improve service quality are paying off. Railroads are hopeful that gains in the fourth quarter will carry over into the first quarter of 2024 and beyond." Excluding coal, carloads were up 45,833 carloads, or 7.9%, in December 2023 from December 2022. Excluding coal and grain, carloads were up 40,036 carloads, or 8%. Total U.S. weekly rail traffic was 370,800 carloads and intermodal units, up 3.4% compared with the same week last year. Total carloads for the week ending December 30 were 182,062 carloads, up 4.1% compared with the same week in 2022, while U.S. weekly intermodal volume was 188,738 containers and trailers, up 2.7% compared to 2022. North American rail volume for the week ending December 30, on 10 reporting U.S., Canadian and Mexican railroads totaled 270,807 carloads, up 5% compared with the same week last year, and 254,475 intermodal units, up 3.8% compared with last year. Total combined weekly rail traffic in North America was 525,282 carloads and intermodal units, up 4.4%. North American rail volume for the first 52 weeks of 2023 was 34,105,519 carloads and intermodal units, down 2.1% compared with 2022. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific Kansas City (CP), Kansas City Southern (KSU), Norfolk Southern (NSC), Union Pacific (UNP), Trinity Industries (TRN), Greenbrier (GBX), FreightCar America (RAIL) and Wabtec (WAB)... Reference Link

13:01 EST Subaru reports December U.S. sales up 1.8% to 57,764 vehicles - Subaru of America reported "17 consecutive months of increased sales" with 57,764 vehicles sold for December 2023, a 1.8% increase compared with a December 2022 total of 56,760 vehicles. Subaru ended calendar year 2023 with 632,086 vehicle sales, a 13.6% increase compared with calendar year 2022.

12:33 EST Honda reports December U.S. sales up 36.5% to 123,388 units - American Honda reports December U.S. sales of 123,388 units, up 36.5% versus last year. American Honda reports 2023 sales up 33.4% to 1.31M units.

12:00 EST Yirendai rises 11.7% - Yirendai is up 11.7%, or 42c to $4.01.

12:00 EST TDCX rises 33.5% - TDCX is up 33.5%, or $1.62 to $6.45.

12:00 EST Livent falls -9.6% - Livent is down -9.6%, or -$1.74 to $16.31.

11:50 EST Equinor, BP to terminate OREC agreement for Empire Wind 2 project - Equinor (EQNR) and bp (BP) announced an agreement with the New York State Energy Research and Development Authority to terminate the Offshore Wind Renewable Energy Certificate Agreement for the Empire Wind 2 project, an offshore wind project in the US with potential generative capacity of 1,260 MW. This agreement reflects changed economic circumstances on an industry-wide scale and repositions an already mature project to continue development in anticipation of new offtake opportunities. The decision recognizes commercial conditions driven by inflation, interest rates and supply chain disruptions that prevented Empire Wind 2's existing OREC agreement from being viable. "Commercial viability is fundamental for ambitious projects of this size and scale. The Empire Wind 2 decision provides the opportunity to reset and develop a stronger and more robust project going forward," said Molly Morris, president of Equinor Renewables Americas. "We will continue to closely engage our many community partners across the state. As evidenced by the progress at the South Brooklyn Marine Terminal, our offshore wind activity is ready to generate union jobs and significant economic activity in New York." The Empire Wind 1 and Empire Wind 2 projects recently reached a key federal permitting milestone, having received the federal Record of Decision from BOEM; last month, Empire Wind 1 also received its Article VII Certificate of Environmental Compatibility and Public Need in New York. Reference Link

11:19 EST General Motors reports Q4 U.S. deliveries up 0.3% to 625,176 units - General Motors and its dealers delivered 2.6M vehicles in the U.S. in 2023, up 14% year-over-year, the company announced. "GM led the industry in total sales and was the top selling manufacturer of trucks, full-size pickups, full-size SUVs, affordable SUVs and fleet vehicles," the company said. "GM has tremendous momentum. We grew our market share in 2023, maintaining strong pricing and low incentives. We led the industry in trucks and had great success with our affordable SUVs like the Chevrolet Trax and Buick Envista, some of today's hottest-selling vehicles. In 2024, we expect industry sales to remain strong and we're excited about the opportunities ahead as we expand customer choice with new vehicles like the Chevrolet Equinox EV and Cadillac Escalade IQ," added Marissa West, GM senior vice president and president, North America. Reference Link

10:49 EST Mazda North America reports December sales up 44.8% to 39,518 vehicles - Mazda North American Operations reported total December sales of 39,518 vehicles, an increase of 44.8% compared to December 2022. Full-year sales totaled 363,354 vehicles; an increase of 23.2% compared to 2022. With 26 selling days in December, compared to 27 the year prior, the company posted an increase of 50.4% on a Daily Selling Rate, or DSR, basis.

10:10 EST Angion Biomedica Corp trading resumes

10:00 EST Redwire rises 7.5% - Redwire is up 7.5%, or 22c to $3.18.

10:00 EST TDCX rises 28.2% - TDCX is up 28.2%, or $1.36 to $6.19.

10:00 EST Xponential Fitness falls -10.2% - Xponential Fitness is down -10.2%, or -$1.29 to $11.36.

09:52 EST Mullen Automotive hits Class 3 delivery target for 2023 - Mullen Automotive announces that for calendar year 2023 Mullen achieved its previously announced Class 3 target with 154 Class 3's built and 141 Class 3's delivered to Randy Marion Automotive Group for a total invoiced amount of $9,196,021. The remaining 13 vehicles are being utilized for engineering and marketing purposes. Mullen THREE production is based out of Tunica, Mississippi, which is home to Mullen's commercial vehicle assembly for both the Mullen ONE, Class 1 EV cargo van, and the Class 3 EV cab chassis trucks.

09:49 EST Florida surgeon general calls for halt to use of mRNA Covid-19 vaccines - Joseph Ladapo, Florida's surgeon general, is calling for a halt to the use of mRNA Covid-19 vaccines. He said via a statement on X, formerly known as Twitter, "The U.S. FDA and the Centers for Disease Control and Prevention have always played it fast and loose with Covid-19 vaccine safety, but their failure to test for DNA integration with the human genome - as their own guidelines dictate - when the vaccines are known to be contaminated with foreign DNA is intolerable." mRNA Covid-19 vaccine makers include Moderna (MRNA) and Pfizer (PFE). Reference Link

09:47 EST Pinstripes falls -10.1% - Pinstripes is down -10.1%, or -$1.34 to $11.97.

09:47 EST Biotie Therapies rises 6.2% - Biotie Therapies is up 6.2%, or 77c to $13.03.

09:47 EST TDCX rises 28.6% - TDCX is up 28.6%, or $1.38 to $6.21.

09:43 EST Prairie Operating Co trading resumes

09:38 EST Pinstripes Holdings Inc trading halted, volatility trading pause

09:34 EST NSPA awards COMLOG contract under European Sky Shield Initiative - The NATO Support and Procurement Agency has awarded COMLOG, a joint venture between Raytheon, and MBDA, their first contract under the European Sky Shield Initiative, or ESSI. With a total value of up to $5.6B, the NSPA contract supports a coalition of nations, including Germany, the Netherlands, Romania and Spain, with a combined quantity of up to 1,000 Patriot GEM-T missiles, if all options are exercised. The contract includes qualification of updated components, addition of new suppliers, test equipment, and spares to support future sustainment. To support delivery, COMLOG will expand the production capacity of GEM-T missiles in Europe.

09:32 EST Knightscope awarded authority to operate by U.S. federal government - Knightscope announced that it has received its Authority to Operate from the Federal Risk and Authorization Management Program, sponsored by the U.S. Department of Veterans Affairs. FedRAMP is a government-wide program that provides a standardized approach to security assessment, authorization, and continuous monitoring for cloud products and services. This achievement means that Knightscope will eventually be listed on the FedRAMP Marketplace as an approved provider for federal agencies as a next step and can also begin its deployment processes to perform on the contract awarded by the VA for its first K5 ASR. "Knightscope's ATO achievement proves our organizational focus on cyber security and our unwavering commitment to our mission of better securing our country," said Mercedes Soria, EVP and Chief Intelligence Officer.

09:27 EST T-Mobile adds Hulu as free streaming service for Go5G Next customers - T-Mobile (TMUS) announced Disney's (DIS) Hulu is joining its suite of complimentary streaming services for Go5G Next customers. "Starting January 24, Hulu and its lineup of thousands of popular TV shows and hit movies will be included at no extra cost as a part of the Un-carrier's most value-packed plan, Go5G Next. And Hulu on Us isn't something customers only get for a few months like some of the streaming benefits other providers offer ... new and existing Go5G Next customers can simply enjoy it as a part of their plan. At no additional cost," T-Mobile stated in a press release. Reference Link

09:27 EST Eco Wave Power sends clean electricity to Israeli National Electric grid - Eco Wave Power Global is pleased to announce that it has commenced sending of clean electricity from its EWP-EDF One project in the Port of Jaffa, to the Israeli National Electrical grid. Eco Wave Power has recently finalized the construction of the EWP-EDF One project in the Port of Jaffa, in Israel. The EWP-EDF One Project was co-funded by EDF Renewable IL, who owns 50% of the project, and by the Israeli Ministry of Energy, which recognized the Eco Wave Power technology as a Pioneering technology. The project has 100KW installed capacity and is comprised of 10 floaters.

09:19 EST Ayro receives first U.S. government order for low-speed electric vehicle - AYRO announces that the Company received its first U.S. Government order for the Company's utility low-speed electric vehicle, the AYRO Vanish, for a United States Embassy located in South Asia.

09:07 EST Dolphin Entertainment's 42West rebrands BHI to Fandoms & Franchises - Dolphin Entertainment has announced the rebranding of independent PR agency Bender/Helper Impact to Fandoms & Franchises. Dolphin Entertainment had acquired the company in 2021, making it the fourth division of 42West.

09:05 EST CleanSpark provides December Bitcoin mining update - December Bitcoin Mining Update (unaudited). Bitcoin mined in December: 720. CY2023 bitcoin mined: 7,391. Total BTC holdings as of December 31: 3,002. Total BTC sold in December: 293. Deployed fleet: 88,924. Month-end fleet efficiency: 26.4 J/Th. Current hashrate: 10.08 EH/s. The company sold 293 BTC in December 2023 at an average of approximately $42,700 per BTC. Sales of BTC equated to proceeds of approximately $12.5M. December daily BTC mined averaged 23.2 and reached a high of 29.8.

09:04 EST Winnebago kicks off 2024 with customer-driven RV lineup - Winnebago is kicking off 2024 with a wave of new products and technologies that will provide RVers with limitless outdoor experiences. With over 100 floorplans on display in Tampa, there's something for everyone - from travel trailers to camper vans to full size Class A motorhomes. Five new products are in the limelight to kick off 2024: View / Navion featuring the all-new Winnebago Connect digital platform, EKKO Sprinter, Revel featuring the all-new Winnebago Power system, Access and the M-Series.

09:03 EST BlackLine names Emily Campbell as Chief Marketing Officer - BlackLine announced that technology industry veteran Emily Campbell has joined the company as chief marketing officer, effective Jan. 2nd. As CMO, Campbell is responsible for driving BlackLine's global marketing strategy as the digital finance transformation leader seeks to capitalize on the growing worldwide demand for solutions that drive greater automation, efficiency, financial governance, and risk management for the Office of the CFO. She will report to Co-CEO Owen Ryan. Campbell comes to BlackLine with more than 25 years of marketing leadership experience, most recently as CMO at Infinite Electronics where she oversaw global brand marketing strategy, e-commerce, customer experience, communications, inside sales, and technical support.

09:03 EST Entravision enters sales partnership with Snap - Entravision (EVC) has entered into a sales partnership with Snap (SNAP). The partnership aims to leverage Snap's advertising solutions and consumer reach in emerging markets such as South Korea, Vietnam and the Philippines. Snapchat continues to grow its community and business operations across Asia-Pacific and this strategic partnership with Entravision will enable brands in these new markets to engage with Snapchatters around the world. Through innovative technology and advertiser solutions, Snapchat allows brands and marketers to connect with 750M users per month.

09:02 EST Hyundai Motor America reports December total sales of 75,164 units, up 4% y/y - Hyundai Motor America reported total December sales of 75,164 units, a 4% increase compared with December 2022 and the highest December sales total in company history. This is the 17th month in a row Hyundai has achieved increases in total sales. Hyundai set total sales records in December for IONIQ 5 (+90%), Santa Fe PHEV (+3205%), Santa Fe HEV (+74%), Tucson (+8%), Tucson PHEV (+8455%) and Palisade (+95%). All-time total sales monthly records were set for Tucson PHEV, Santa Fe PHEV and Palisade.

09:01 EST LPL Financial: Zachary Fiandt joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisor Zachary Fiandt CFP, CIMA has joined LPL Financial's broker-dealer, RIA and custodial platforms, aligned with Financial Partners, Inc., an existing firm that's part of Exemplar Financial Network. Fiandt reported having served approximately $260M in advisory assets and joins LPL from PNC Private Bank Trust.

08:53 EST LQR House reports 458% y/y revenue increase in December - LQR House announces a 458% YOY increase in revenue for December 2023 compared to December 2022. This achievement aligns with The National Retail Federation's forecast, projecting record-breaking holiday spending between $957.3 billion and $966.6 billion during November and December 2023. In December 2022, LQR House recorded revenue at $74,053, and the Company has witnessed a significant growth to $339,713 in December 2023. We believe that this accomplishment is not isolated but part of a broader trend, evidenced by record-breaking sales over the Black Friday to Cyber Monday weekend where November's monthly revenue surged over 300% year-over-year. In our view, these results indicate that this is not a one-time occurrence for LQR House, but rather, we believe it's evolving into a recurring situation where LQR House is actively cultivating consistent momentum.

08:50 EST AMA grants Cardio Diagnostics CPT PLA reimbursement code for Epi+Gen CHD - Cardio Diagnostics Holdings announced that the American Medical Association AMA has granted and assigned a dedicated Current Procedural Terminology Proprietary Laboratory Analysis code, 0439U, for the company's AI-driven coronary heart disease CHD event risk assessment test, Epi+Gen CHD... Receipt of this new CPT PLA code, which will be effective on April 1, 2024, is a significant step toward payer billing and payment, facilitating broader adoption of the first and only AI-powered integrated genetic-epigenetic clinical blood test for evaluating the likelihood of a patient experiencing a CHD event, mainly a heart attack, within the next three years....Primary Prevention of Heart Attacks: The Clinical and Economic Benefits of Epi+Gen CHD In peer-reviewed studies, Epi+Gen CHD was more cost-effective and more sensitive for assessing heart attack risk compared to standard lipid-based risk calculators. Specifically, in a validation study conducted with Intermountain Healthcare, Epi+Gen CHD was shown to be, on average, about twice as sensitive in detecting risk for a CHD event in women than lipid-based calculators. "Cardio Diagnostics is committed to driving widespread adoption of our solutions, and obtaining a reimbursement code for Epi+Gen CHD is a critical milestone in our commercialization strategy and for gaining reimbursement from federal and private payers," said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. For employers, this means potentially greater access to a technology that enables a healthier workforce and significant savings in healthcare costs related to heart disease. Cardio Diagnostics continues to lead the way in precision cardiovascular medicine, leveraging the power of AI and epigenetics to help prevent heart attacks.

08:47 EST American Resources affiliated company Novusterra partners with Kenai Defense - American Resources Corporation announced that their affiliated company, Novusterra announced that its patented technology to produce carbon nanomaterial additives for concrete and asphalt pavements is being used as the exclusive patented technology in a comprehensive research project to improve the future durability of airfields for the United States Air Force.

08:46 EST Scynexis reports binding MOU with GSK for amendment to license agreement - In a regulatory filing, Scynexis (SCYX) disclosed that on December 26, 2023, the company and GlaxoSmithKline Intellectual Property Limited (GSK) entered into a binding memorandum of understanding for amendment to the exclusive license agreement between Scynexis and GSK, dated March 30, 2023. Pursuant to the terms of the License Agreement, Scynexis granted GSK an exclusive, even as to Scynexis and its affiliates, royalty-bearing, sublicensable license for the development, manufacture, and commercialization of ibrexafungerp, including the approved product BREXAFEMME, for all indications, in all countries other than Greater China and certain other countries already licensed to third parties. The License Agreement is being amended in connection with the delay in the commercialization of BREXAFEMME and further clinical development of ibrexafungerp associated with this event. Pursuant to the License Agreement, Scynexis has already received an upfront payment of $90M and a development milestone payment of $25M, the filing noted. Reference Link

08:44 EST Sigma Additive Solutions completes acquisition of NextTrip - Sigma Additive Solutions announced the completion of its acquisition of NextTrip Holdings, Inc., a travel technology company based in Sunrise, Florida, through a previously announced share exchange. The acquisition, which was first announced October 2023, closed on December 29, 2023, at which time NextTrip became a wholly owned subsidiary of the Company. Additionally, effective upon closing of the acquisition, Jacob Brunsberg, President and CEO of Sigma, resigned from such roles, and Bill Kerby, CEO of NextTrip, was appointed a CEO of Sigma. Mr. Brunsberg will continue to serve as a director on Sigma's board. On December 28, 2023, at Sigma's 2023 annual meeting of shareholders, Sigma shareholders voted to approve the issuance of shares of Sigma common stock associated with the acquisition of NextTrip, pursuant to the Share Exchange Agreement entered into with NextTrip and certain other parties in October 2023, and to further approve the terms of such Share Exchange Agreement.

08:42 EST One Stop Systems joins two key U.S. DoD consortiums, SCEC and SOSSEC - One Stop Systems has been accepted as a member of two US Department of Defense, DoD, business consortiums, the System of Systems Consortium, SOSSEC, and the Sensors, Communications, and Electronics Consortium, SCEC. These consortiums were formed to address the technology procurement requirements of the DoD, including facilitating research and development, technology demonstrations and prototype projects.

08:41 EST NightHawk subsidiary commences work on contract for leading university - NightHawk Biosciences announced its Scorpius BioManufacturing subsidiary has commenced work on a contract that it was awarded by a leading university to develop and manufacture a novel biologic targeting substance use disorder, which includes drug, alcohol and opioid addiction. Jeff Wolf, CEO of NightHawk, commented, "We are honored to have been awarded this multi-million dollar contract by one of the foremost research universities in the United States. Scorpius was selected due to its process development and large molecule manufacturing expertise, as well as its flexibility and dedication to customer service. We are off to a strong start and look forward to expanding this relationship into additional programs in 2024 and beyond. Overall, we could not be more excited by the traction and growing pipeline within Scorpius."

08:40 EST NetSol Technologies says Haydock Finance subscribes to Dock, Lane - NETSOL Technologies announced that existing customer Haydock Finance has signed up for two additional products from NETSOL's Appex Now marketplace - Dock and Lane. Dock is a centralized document generation tool with template-based configuration and simple syntax, allowing users to create accurate documents in just seconds. Lane offers a feature-rich, end-to-end order management system for asset leasing/loans and credit companies.

08:39 EST Clever Leaves granted Australian GMP certification for cannabis products - Clever Leaves Holdings has been granted Australian GMP certification for its facilities in Colombia by the Therapeutic Goods Administration, the regulatory body for health products in Australia. This certification authorizes Clever Leaves to manufacture cannabis products for patients in Australia, marking a significant achievement for the multinational operator. Similar to the stringent standards of the EU-GMP certification, the Australian GMP certification from the TGA ensures the delivery of the highest quality medicinal cannabis to patients. It safeguards against product contamination, variations in compound concentrations, mix-ups, incorrect labeling, and other potential issues. This certification is a prerequisite for the manufacturing and commercialization of cannabis products in the Australian market.

08:38 EST Sidus Space gets NOAA okay to provide imaging services to governments - Sidus Space announced that the National Oceanic and Atmospheric Administration NOAA has granted Sidus a Tier 1 remote sensing license to include Panchromatic PAN and Shortwave Infrared SWIR imaging capabilities. This approval includes Sidus' upcoming LizzieSat scheduled for launch in March 2024, as well as subsequent LizzieSat satellites....Through this new license authority, Sidus LizzieSat satellites will collect and distribute images and data to government and commercial customers supporting a wide range of applications. "NOAA's Tier 1 remote sensing license approval is a significant milestone for Sidus Space. With PAN and SWIR imaging capabilities, we're focused on our commitment to practical innovation in space technology while addressing real world challenges," said Carol Craig, CEO and Founder of Sidus Space. LizzieSat is expected to launch in March 2024 on SpaceX's Transporter-10 mission from Vandenberg Space Force Base, California and remain in space for data collection for four years of operation.

08:38 EST Oatly Group announces nationwide availability at The Coffee Bean & Tea Leaf - Oatly Group announced a new foodservice distribution arrangement with The Coffee Bean & Tea Leaf Brand, one of the world's leading roasters and retailers of specialty coffee and tea. "We're thrilled to bring Oatly to customers of The Coffee Bean & Tea Leaf, an iconic brand that cherishes a great coffee experience just like we do," said Mike Messersmith, President, Oatly North America. "With our roots in the US inextricably tied to the coffee channel, we are so happy to continue widening our presence in this space."

08:37 EST Verint awarded $49M from U.S. healthcare company - Verint announced the booking of a contract valued at more than $49M from a U.S. healthcare company to increase customer experience automation in their customer operations.

08:36 EST Financity facilitated increase of Accounts Receivable Securitization Program - Finacity Corporation announced that it has facilitated an increase from $1.1 billion to $1.5 billion of the commitment capacity, with an accordion feature of an additional $1 billion, for the Accounts Receivable Securitization Program of Bunge Global SA, a leading global agribusiness and food company. As part of the process, Finacity also supported the addition of 2 new seller countries, Mexico and Poland, and 7 new subsidiary company originators for Bunge in its Program. Pricing for the Program includes premiums or discounts to the applicable margin tied to certain sustainability criteria, including, but not limited to, science-based targets that define Bunge's climate goals within its operations and a commitment to a deforestation-free supply chain in 2025.

08:36 EST Disney confirms Blackwells Capital intent to nominate three directors to board - Disney confirmed that Blackwells Capital, together with its affiliates, has provided notice of its intent to nominate three individuals for election to the company's board of directors at the 2024 annual meeting of shareholders. The governance and nominating committee, which evaluates director nominations, will review the proposed Blackwells nominees and provide a recommendation to the board as part of its governance process. The company expects to file preliminary materials with respect to the 2024 annual meeting of shareholders with the Securities and Exchange Commission, which will include the board's recommended slate of director nominees. Disney shareholders are not required to take any action at this time.

08:35 EST Nano Dimension says Reshaping Nano Initiative 'well underway' - The company said, "The Initiative has the following objectives: Achieving positive operating income in early 2025, and Reducing cash burn comparing to 2023 by approx. 75%-85%, Expecting to reach cash flow positive post A above. Nano Dimension is able to achieve this as it has reached greater scale and synergies on the back of its robust M&A program to date. Only three years ago, Nano Dimension was a niche company focused on additively manufactured electronics. Today the Company is an advanced manufacturing leader as a pioneer in AME along with cutting-edge solutions for precision-additive manufacturing solutions, complemented by sophisticated and proven solutions in Additive Electronics and print systems, which are all brought together by a vision to apply our internally developed deep learning-based DeepCube/Deep Learning AI wherever possible. This is reflected in our financials with revenue going from $3.4 million in 2020 to $56.2M million this year, with approx. 29% organic growth over the last 12 months. During Q4/2023 The Company's workforce worldwide was reduced by approximately 25%, The Executive Management group of the Company was reduced by 25%. With greater scale and organizational efficiencies, we have already completed plans that looked critically at our costs of goods sold and operating expenses. You should expect to see a portion of the full year expected savings of $30 million in our results for Q1/2024. We want to highlight that the Initiative was crafted around setting financial objectives that reflect the maturity of our different groups and product lines, which allows us to stay focused on our innovation driven growth engines that make Nano Dimension such an exciting company."

08:33 EST Safe & Green CEO provides letter to shareholders - "Safe & Green Holdings provided the following letter to stockholders from Paul Galvin, the Company's Chairperson and CEO: "We are pleased to share with you the significant milestones and exciting developments that Safe & Green Holdings accomplished in 2023 as well as take a look at what we believe is a very promising future for the Company in 2024. 2023 was a busy and exciting year for Safe & Green Holdings, including the spin-off of Safe and Green Development Corporation into a separate, publicly traded entity, which involved more than a year of dedicated effort and hard work from the Safe & Green team. With a robust construction pipeline exceeding $800 million and record growth, we have expanded our manufacturing capabilities to meet the increasing demand... Looking towards 2024, the prospects for Safe & Green Holdings are promising thanks to our current involvement in numerous projects. Our revenue from manufacturing and construction services has grown substantially and we are confident in the scalability of our business model and eager to continue expanding our presence across the United States. The outlook for the Company is bright, and we remain dedicated to managing our expenses wisely and enhancing stockholder value for our long-term stockholders. I want to express my heartfelt gratitude to our Board of Directors and the entire Safe & Green Holdings team for their relentless efforts and significant contributions to the Company's achievements over the past year."

08:32 EST TC Biopharm announces additional cost reduction steps, 50% headcount reduction - TC BioPharm announced that the company is undertaking a series of initiatives to reduce costs and drive efficiency in order to reduce cash burn and expand its financial runway. TC BioPharm's Overhead Reduction Plan includes: Scaled down Research and Development to strictly process development for commercial applications and manufacturing; Implementing a focused manufacturing platform targeting only product needed to complete ACHIEVE trial in 2024; Further streamlining the organization to drive process-related efficiencies; Reduction of headcount by approximately 50%. As a result of these challenging but necessary changes to the organizational structure, dedicated team members will be impacted as the company operates with a reduced headcount moving forward. "Management is implementing these initiatives in order to significantly reduce our cash-burn as we prioritize our immediate objective of advancing our lead therapeutic to the nearest data inflection point, specifically the ACHIEVE trial interim review," said, Bryan Kobel, CEO of TC BioPharm. "Our immediate goal is pursuing the most cost effective and time efficient milestones, which under review will be the ACHIEVE trial currently underway in the UK. These cost reduction initiatives are expected provide us with the necessary time to realize the value the team have created and hopefully for the biotech headwinds to subside. I regret having to launch such a stringent undertaking, but it would be fiscally irresponsible to continue without these measures. This is not a reflection of any of the employees, their hard work or their competency, we have a stellar group of individuals who have continually hit their milestones, unfortunately the public markets continue to be difficult to navigate and as a consequence, these steps are being taken immediately to preserve cash."

08:28 EST iCoreConnect acquires FeatherPay, terms not disclosed - iCoreConnect has acquired FeatherPay, a provider of digital patient payments and billing technology. This strategic acquisition marks a significant expansion of iCoreConnect's portfolio into the fintech sector, further solidifying its position as an innovator in technology solutions. In conjunction with this acquisition, iCoreConnect is proud to unveil its new Fintech division, iCorePay. The Company announced that Craig Haynor, CEO and Founder of FeatherPay, will be joining iCoreConnect to lead the new Fintech division. The new division will focus on developing and enhancing financial technology solutions within the healthcare industry. FeatherPay will serve as the cornerstone of this new division, bringing its expertise and cutting-edge technology to the forefront of iCoreConnect's fintech initiatives. FeatherPay's industry-best Product and Engineering team will also be joining iCoreConnect in the acquisition.

08:27 EST Catheter Precision terminates CFO Passey, appoints Thomassen as interim CFO - Catheter Precision announced changes to the executive management and board of directors, including a change to the CFO. Mr. Passey's employment was terminated effective December 31, 2023. In his place, the Board of Directors has appointed Margrit Thomassen, CPA, to be interim CFO as of January 2, 2024. Margrit has been a full-time employee at the Company's Catheter Precision subsidiary since 2019 and has served as controller of the Company since the acquisition of Catheter Precision by Ra Medical in January 2023.

08:24 EST Macau reports December casino revenue up 433.3% to 18.57B patacas - Earlier in the week, Macau's gaming bureau reported December gross revenue from games of fortune in the region was up 433.3% year-over-year to 18.567B patacas. Publicly traded companies in the Macau gaming space include Las Vegas Sands (LVS), MGM Resorts (MGM), Wynn Resorts (WYNN) and Melco Resorts (MLCO). Reference Link

08:20 EST AC Immune provides update on program progress, says key milestones in 2024 - AC Immune provided an update on positive progress in its active immunotherapy programs, with three Phase 2 trials progressing to key clinical milestones in 2024. ACI-24.060: AC Immune's wholly-owned anti-amyloid beta active immunotherapy-candidate. The six-month Abeta positron emission tomography imaging results are expected in H1 2024, and the 12-month Abeta PET data are expected in H2 2024. ACI-7104.056: AC Immune's wholly-owned anti-alpha-synuclein active immunotherapy, to treat Parkinson's disease. Safety and immunogenicity updates from the trial will be reported in H2 2024. ACI-35.030: AC Immune's partnered investigational targeted active immunotherapy, selective for pathological phosphorylated Tau. Under the terms of the licensing agreement, AC Immune has received a milestone payment of CHF15 million and expects to receive another milestone payment of CHF 25 million related to achieving an undisclosed enrollment target in 2025.

08:19 EST Collegium Pharmaceutical board authorizes $150M share repurchase program - Collegium's board of directors authorized a new share repurchase program to repurchase up to $150.0 million in common stock over 18 months.

08:16 EST Delaware Lottery launches online sports betting powered by Rush Street - Following a successful soft launch on December 27, the Delaware Lottery announced the launch of its first online sportsbooks along with the relaunch of its three online casinos, ushering in a new era of online gaming in the First State. The new online casinos and online sportsbooks are powered by Rush Street Interactive. In addition to the introduction of online sports betting in Delaware, the State's three casinos now offer a revamped array of exciting new online casino games. Customers across Delaware, aged 21 and older, can place bets on all mobile devices, tablets, desktop and laptop computers. "We are thrilled to begin this historic and much-anticipated launch of the new online sportsbook and casino with the Delaware Lottery and bring our award-winning product to Delaware," said Richard Schwartz, Chief Executive Officer of RSI. "With our extensive offering of gaming content, wide range of deposit and withdrawal methods, real-time cash-out approvals, and best-in-class customer service, Delaware customers are going to love the convenience of wagering on their favorite sports, slots, and table games from anywhere in the state."

08:15 EST Acrivon Therapeutics appoints Cuillerot as Chief Medical Officer - Acrivon Therapeutics announced the appointment of Jean-Marie Cuillerot, M.D., as chief medical officer. Dr. Cuillerot was previously the chief medical officer at Dragonfly Therapeutics where he established and led a clinical team advancing multiple potential first-in-class assets.

08:13 EST WiMi Hologram Cloud develops RPSSC technology - WiMi Hologram Cloud developed RandomPatchSpatialSpectrumClassifier technology to fully utilize the complementarity between spatial and spectral information. The R&D of WiMi's RPSSC combines a 2D Gabor filter and a random patch convolution feature extraction method. First, the RPSSC uses principal component analysis and LDA algorithms to downscale the original hyperspectral image. The purpose of this step is to eliminate redundant spectral information while retaining the main information, increase the inter- and intra-class distance ratios, and prepare data for subsequent feature extraction and classification. On the dimensionalized image, RPSSC introduces a two-dimensional Gabor filter. Gabor filters are widely used in the field of computer vision to extract spatial structural features such as edges and textures of images. Through the Gabor filter, the RPSSC technology can capture the local texture and spatial information in the image, which lays the foundation for the subsequent feature extraction. Next, employed the GRPC method to the RPSSC, which takes Gabor features as input. Random patch convolution realizes the extraction of multilevel spectral features from an image by randomly selecting patches in the image and performing convolution operations on these patches. This step aims to synthesize spatial and spectral information, allowing the model to understand the features of the image more comprehensively. Finally, the RPSSC technology fuses the spatial features extracted from the GRPC with the multilevel spectral features. Through this fusion process, the model is able to synthesize the spectral information and local spatial structure information to provide a richer feature representation for image classification. Ultimately, RPSSC employs a support vector machine (SVM) classifier to classify the fused features to achieve accurate classification of hyperspectral images.

08:12 EST Ultragenyx announces completion of enrollment in Phase 1/2 trial of GTX-102 - Ultragenyx Pharmaceutical announced the completion of patient enrollment in its Phase 1/2 clinical trial of GTX-102 for the treatment of pediatric patients with Angelman syndrome, AS. The dose-expansion cohorts have enrolled 53 patients for a total of 74 patients enrolled globally in the Phase 1/2 trial. GTX-102 is an investigational antisense oligonucleotide delivered via intrathecal administration and is designed to target and inhibit expression of UBE3A antisense transcript, UBE3A-AS. "With completion of enrollment in the Phase 1/2 trial, we remain on track to report results in the first half of 2024 from at least 20 expansion cohort patients on therapy for a minimum of 6 months. We are confident that the cumulative safety and efficacy data will allow for dose and endpoint selection to support our Phase 3 program," said Eric Crombez, M.D., chief medical officer at Ultragenyx. "We appreciate the support of the Angelman community, including the patients, families and healthcare providers, as we urgently work together to develop a new treatment option that may be able to improve the quality of life of those impacted by this devastating disease."

08:11 EST 4D Molecular, Arbor Biotechnologies establish partnership to co-develop - 4D Molecular Therapeutics and Arbor Biotechnologies announced a strategic partnership focused on advancing new AAV-based gene-editing therapies for central nervous system, CNS, diseases with high unmet medical needs in both rare and common disease populations. 4DMT and Arbor will co-develop and co-commercialize up to six AAV-delivered CRISPR/Cas-based therapeutic candidates, with the costs and profits shared evenly based on mutually agreed plans. Arbor will lead research, development and, if approved, commercialization efforts on the first product candidate in the collaboration, which will address a molecular target implicated in amyotrophic lateral sclerosis. 4DMT will lead research, development and, if approved, commercialization efforts on the second product candidate. "The recent landmark FDA approval of the world's first CRISPR-based treatment is a revolutionary event for genetic medicines and the biotech industry. Gene editing technology continues to rapidly advance and we believe the safe and efficient delivery of these potentially transformative therapies can address CNS diseases of high unmet need," said David Kirn, M.D., Co-Founder and Chief Executive Officer of 4DMT. "Arbor is at the forefront of this rapid innovation, and they have discovered and optimized gene editing payloads that are compact enough to be delivered within a single AAV vector. We look forward to combining our complementary technologies and capabilities to power a new generation of potential genetic medicines. This collaboration provides us with the opportunity for next-generation gene editing capabilities and CNS products, while simultaneously allowing us to maintain our focus on clinical development in large market ophthalmology and pulmonology."

08:10 EST Keros Therapeutics to develop KER-065 for treatment of obesity - Keros Therapeutics announced that it plans to develop KER-065, a novel ligand trap designed to bind to and inhibit TGF-ss ligands, including myostatin and activin A, for the treatment of obesity. "Obesity is a complex and chronic disease associated with numerous comorbidities and a growing prevalence in patients. We believe there is a need for additional treatment options, including one that leads to weight loss without an associated loss of muscle and a potential for frailty. Based on our preclinical data, we believe that KER-065 has the potential to treat obesity without those limitations, by increasing skeletal muscle, reducing fat mass through an increase in energy expenditure, improving insulin sensitivity and improving cardiac function," said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer of Keros. "To that end, we recently commenced our Phase 1 clinical trial evaluating KER-065 in healthy volunteers and, following its successful completion, plan to initiate a proof-of-concept trial of KER-065 in obese patients."

08:09 EST Mesa Labs completes the acquisition of GKE Science & Technology - Mesa Laboratories announced the completed acquisition of GKE-GmbH's sterilization indicators business and its accredited, independent testing lab SAL GmbH on October 16th, 2023. Today, Mesa announced the completion of the acquisition of GKE's Chinese sales entity, Beijing GKE Science & Technology effective December 31, 2023, which completes all related transactions. Together, the entities are referred to as "GKE." The three GKE entities are expected to add EUR 19-EUR 20 million of revenues over the next 12 months and deliver mid-single digit organic revenues growth over the next several years. Excluding the impact of purchase accounting and integration expenses, we expect gross profit as a percentage of revenues to be in line with our existing SDC business and adjusted operating income1 as a percentage of revenues to approach 37%-40% over the next 12 months.

08:08 EST Safety Shot announces brand activation event at Coachella - Safety Shot announced its inaugural brand activation with "Safety Shot House" at the Coachella Valley Music and Arts Festival on April 12 - 14, 2024. One of the highest profile events in the music and arts world, Coachella attendees, an estimated 250,000 over both weekends, are an ideal demographic for Safety Shot, the world's first patented drink that helps people feel better faster by reducing blood alcohol content and boosting clarity. Safety Shot joins other global beverage brands that have created activations at Coachella including Heineken, Patron, Don Julio, 818 Tequila, Aperol Spritz, and Evian.

08:07 EST Egan-Jones: SomaLogic holders should vot 'against' Standard BioTools deal - Madryn Asset Management a holder of approximately 4.2% of the outstanding common stock of SomaLogic (SLGC), announced that Egan-Jones Proxy Services an independent proxy advisory firm, has recommended shareholders vote AGAINST the proposed merger with Standard BioTools (LAB) at the Company's Special Meeting of Shareholders on January 4. In its report, Egan-Jones noted: "Egan-Jones views the proposed transaction to be untimely and inadvisable in terms of maximizing shareholder value." "We believe that the proposed merger agreement was a result of an insufficient search process due to the presence of conflict[s] of interests, which we view as detrimental to the assessment of the true value of the Company." "Assuming that the merger will be consummated, Eli Casdin and Casdin Capital, will retain their valuable Series B Preferred Put-Right in the pro forma combined entity."..Mr. Casdin's ties with certain members of the Transaction Committee makes the process' integrity questionable." "...the merger significantly undervalues the Company's worth... We believe that there is a crucial discount to the premium and to the Company's value as well." "...SomaLogic is better off as a stand-alone company, in the absence of a significantly higher offer." Avinash Amin, Managing Partner of Madryn Asset Management, stated: "Egan-Jones clearly recognizes that the Proposed Merger is inherently flawed and not in the best interests of SomaLogic or its shareholders. We are pleased that Egan-Jones has joined the chorus of shareholders who have publicly opposed the Transaction due to its numerous failings, including an inadequate process, poor governance and blatant undervaluation of SomaLogic. We urge our fellow shareholders to follow Egan-Jones' independent recommendation and vote against this Transaction."

08:07 EST Trio Petroleum commences production of two wells in South Salinas project - Trio Petroleum provided updates on its HV-1 confirmation well and its HV-3A discovery well in the Company's South Salinas Project. On December 27, the Company moved a rig onto location at its South Salinas Project to begin a workover of its HV-1 well, and subsequently the rig will move to its previously drilled HV-3A well. The Company estimates both wells should be producing on pump in mid- to late-January. A pumping unit and temporary facilities are already installed at the HV-1 well site and are now being reinstalled at the HV-3A well site. The HV-1 was drilled as a two-mile step-out from the previously drilled HV-3A well. The HV-1 location was chosen based on interpretation of 3-D seismic data with the goal of better defining the magnitude of the Presidents Field located in the large 9,267 acre South Salinas Asset in which Trio owns an 85.75% working interest. During the drilling and testing of the HV-1 well, the Company was excited by the oil shows and swab testing results of the Mid-Monterey-Clay, a zone previously not assigned any value in the Company's reserve report, but which swab tested at rates of up to approximately 125 barrels of oil per day. The swabbing operations were short-term and are not necessarily indicative of long-term production capacity and, therefore, the Company plans to further test the zone by putting it on pump and producing from this new zone. The Company believes production from this zone will further increase the reserves and PUDs of the Company's current approximate $2 billion PV reserve value. The workover of the HV-1 well will isolate existing perforations in the Mid-Monterey-Clay at 6,390-6,560 feet depth from perforations in shallower zones, allowing the Company to then production test the Mid-Monterey-Clay by putting it on pump. Recently, Company management revisited the exploration permit for the HV-3A well and determined that production of the well could resume, and that a majority of the permitted eighteen-month test-period remains. This unexpected, but very favorable, outcome enables the Company to produce from two wells, the HV-1 and HV-3A, much earlier than expected. The Company is currently improving the road to the HV-3A well site, reinstalling temporary facilities, and putting the well back on pump. There are currently 250 feet of open perforations in the HV-3A well, of which 125 feet are in the Yellow Zone and 125 feet are above the Yellow Zone in the Upper-Monterey-Clay. Earlier production testing on pump of these same HV-3A perforations recovered 18.5 degrees to 22.4 degrees API gravity oil at rates up to 154 BOPD, with the average over the final two weeks being 33 BOPD plus 86 barrels of water per day. The future production of the HV-3A well could be improved as the perforations have not yet been acidized for borehole-cleanup and there are significant behind-pipe intervals in the well that have not yet been perforated. The Company intends to production test the existing open perforations on pump and to then take steps, as may be appropriate, to increase oil and gas production at the well, such as acidizing for borehole-cleanup, adding new perforations, and/or opening existing deeper perforations that previously produced oil and that are currently below bridge plugs.

08:06 EST CymaBay: Analysis of Phase 3 ENHANCE study published in Hepatology - CymaBay Therapeutics announced the first published findings demonstrating the impact of seladelpar on serum interleukin-31 levels and its correlation with pruritus improvement in people with primary biliary cholangitis. Seladelpar is a first-in-class oral, selective PPARdelta agonist being investigated for the treatment of patients with PBC. The latest findings from a post-hoc analysis of the Phase 3 ENHANCE study, were published today in the open access journal Hepatology and are the first peer-reviewed published report of a correlation in decreases in IL-31, bile acids and pruritus symptoms in PBC following treatment with an investigational agent. In a post-hoc analysis of the Phase 3 ENHANCE study, IL-31 serum levels were measured in people with PBC who received daily oral doses of seladelpar 5 mg (n=53), 10 mg (n=53) or placebo (n=55) for three months. IL-31 is a cytokine known to mediate pruritus and blocking IL-31 signaling can provide relief in pruritic skin diseases. Statistically significant dose-dependent decreases in IL-31 were observed with seladelpar 5 mg (-30%, p=0.0003) and 10 mg (-52%, pless than0.0001) compared to placebo (+31%) in the study. IL-31 levels correlated with pruritus intensity using a numerical rating scale (NRS, 0-10; r=0.54, pless than0.0001). Participants who experienced an improvement in pruritus (decrease in NRS of 2 or more) demonstrated greater dose-dependent reductions in IL-31 compared to those without pruritus improvement (decrease in NRS of less than 2).Baseline IL-31 levels also closely correlated with total (r=0.54, pless than0.0001) and conjugated bile acids (up to 0.64, pless than0.0001). Strong correlations were also observed between changes in IL-31 levels and changes in total bile acids (r=0.63, pless than0.0001) and conjugated bile acids in the seladelpar 10 mg group.

08:05 EST Consolidated issues letter to shareholders encouraging vote for Searchlight deal - Consolidated Communications has mailed a letter to its shareholders in connection with its upcoming special meeting of shareholders. Consolidated is reminding shareholders to vote for the proposed acquisition of the company by affiliates of Searchlight Capital Partners and British Columbia Investment Management Corporation. The special meeting is scheduled to be held on January 31. Shareholders of record as of December 13, 2023, are entitled to vote at the special meeting.

08:03 EST Lead Real Estate reports 'positive' response from Shanghai property show buyers - Lead Real Estate reported that the Company received a strong attendee turnout in its exhibit booth at the Shanghai Luxury Property Show Real Estate Exhibition held in China from December 8 to December 10, 2023. More than 100 potential customers, including Chinese luxury home and hotel buyers, visited LRE's booth at the Shanghai LPS, and many expressed interest in the Company's properties. Among these properties was LRE's newest and best-selling condominium, Excelsior Yoyogi-Koen-mae, which has a selling price of 1.298 billion Japanese yen, or approximately $9.1 million, per unit. A prominent Chinese real estate buyer is currently visiting Japan to view this property, as well as several other luxury LRE condominiums, according to the Company.

08:02 EST Worksport announces strategic parntership with NeuronicWorks - Worksport announce that it has formed a strategic partnership with NeuronicWorks to manufacture and assemble the COR battery system in preparation for the system's anticipated Alpha release. Along with supplying Worksport's circuit boards for the COR hub, NeuronicWorks will perfect the construction of the full unit. COR's Alpha release, which will allow real-world testing and first-hand user experiences, is intended to be a pivotal step towards the manufacturing of the COR system in Canada, and eventually launching it using both international and domestic parts. "Selecting a high-tech manufacturing partner like NeuronicWorks is a big step for Worksport on the road to the eventual market introduction of the revolutionary and world-beating SOLIS solar light truck cover and its companion COR battery system," said Worksport CEO Steven Rossi. "We are thrilled to be partnering with such a distinguished electronic engineering leader and benefit from its substantial track record in bringing to market highly advanced proprietary products. Assembling the COR system in Canada in partnership with this leading electrical engineering company is a testament to our commitment to quality and sustainability. By bringing assembly to Canada, we have further strengthened our position in the renewable energy sector."

07:52 EST Clubhouse Media reports HoneyDrip.com active users up 5% in December - Clubhouse Media Group announced that HoneyDrip.com has seen month over month growth, continuing into December 2023. Honeydrip.com is a digital platform designed and wholly owned by CMGR with a focus on the empowerment of creators. The site allows creators to connect and engage with fans and monetize exclusive content. HoneyDrip.com has experienced rapid growth in four main categories during the month of December 2023 alone: 1) Active performers on the site increased by 4%; 2) Content posts to be sold increased by 6%; 3) Active users increased by 5%; 4) Applications from creators wishing to join the site increased by 3%.

07:49 EST Laser Photonics receives order from OPG Nuclear Division - Laser Photonics announced it received an order from Ontario Power Generation's, or OPG, Nuclear Division for its MarkStar Pro laser marking system.

07:37 EST Rekor Systems completes acquisition of All Traffic Data Services - Rekor Systems has completed the acquisition of All Traffic Data Service, further solidifying its expertise in transportation data collection and analytics. ATD collaborates closely with numerous traffic engineering firms, metropolitan planning organizations, municipalities, and state Departments of Transportation, where Rekor currently lacks a sales presence. They are actively involved in data collection across a wide-ranging geographic area, encompassing states like California, Colorado, Arizona, Nebraska, Nevada, Oregon, and Washington. This addition expands the coverage of Rekor's urban mobility operations across the country's western region. Further, it strengthens its position in the Southeast, providing ready access to experienced urban mobility personnel and operational facilities to support the expansion of its IoT network. This acquisition follows Rekor's 2022 acquisition of Southern Traffic Services, demonstrating the Company's commitment to shaping the future of urban mobility. The new addition will combine two complementary data collection companies under the Rekor banner. This is anticipated to accelerate Rekor's business plan and path to profitability going forward. It combines over 30 years of traffic engineering and data collection expertise with Rekor's next-generation artificial intelligence and machine learning technologies. The combination of local presence, experienced resources, and new technology uniquely positions the Company to become the leading provider of artificial intelligence and machine learning-driven solutions for traffic management, urban mobility, and public safety for departments of transportation in the United States. In conjunction with this transaction, Drew Meyers, a Partner at Seaport Capital, has been appointed to the Rekor Board of Directors. The acquisition is valued at $19 million through a combination of cash and stock. ATD will operate as a business unit within Rekor, leveraging its existing team of approximately 41 employees across offices in 14 states. For fiscal year 2023, ATD is expected to generate approximately $9.5 million in revenue and an estimated $3 million in EBITDA.

07:36 EST Arch Biopartners gets Turkish MOH approval for Phase II trial of LSALT peptide - Arch Biopartners has received approval in Turkey from the Ministry of Health to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury. LSALT peptide is the Company's lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver. With the Ministry of Health approval for the trial, Arch can now proceed to contract and activate clinical sites in Turkey. Patient enrollment is planned to start in February 2024.

07:34 EST Elektrofi, Janssen Biotech enter collaboration, license agreement - Elektrofi has entered a multi-target worldwide research collaboration and license agreement with Janssen Biotech, a Johnson & Johnson company. This collaboration will initially focus on developing an at home self-administered subcutaneous version of a lead oncology asset. The agreement was facilitated by Johnson & Johnson Innovation. Under the terms of the agreement, Elektrofi will receive an upfront payment of $18 million in exchange for Janssen receiving the exclusive right to a lead Janssen oncology target and up to four additional targets. Elektrofi will be eligible to receive future milestones surpassing $155 million per target, subject to achieving developmental, regulatory, and sales-based milestones, as well as a tiered upper mid-single digit royalty on global net sales for commercialized products. Janssen will be responsible for each product's clinical development and commercialization. The strategic partnership with Janssen further expands the use of Elektrofi's innovative formulation technology platform. Through its collaborations with leading pharmaceutical companies, Elektrofi has the potential to develop up to 12 unique products with its partners.

07:32 EST Verrica Pharmaceuticals announces specialty pharmacy agreement with Walgreens - Verrica Pharmaceuticals (VRCA) announced that it is growing its distribution network by entering into an agreement with Walgreens (WBA) to distribute YCANTH through its specialty pharmacy. Walgreens joins Verrica's existing specialty pharmacy, Nufactor, who continues to be instrumental in helping the Company build awareness of YCANTH therapy among high volume dermatology and pediatric medical practices. "We are excited to enter into this agreement with Walgreens to help bring the first FDA-approved therapy for the treatment of molluscum contagiosum, YCANTH, to the millions of adults and children who contract this viral skin disease each year," said Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals. "Walgreens and Verrica mutually recognize the need to address this significant unmet medical need in dermatology, and we look forward to working together to provide greater access to YCANTH for patients in need. We will also continue to work closely with Nufactor, our other Specialty Pharmacy, who continues to be an extraordinary partner."

07:31 EST BridgeBio announces FDA clearance of IND application for BBO-8520 - BridgeBio Pharma has announced that the United States Food and Drug Administration, FDA, has cleared the investigational new drug, IND, application for BBO-8520, a first-in-class orally bioavailable and highly potent small molecule direct inhibitor of KRASG12C ON state. BBO-8520 binds covalently to the Switch II pocket in both the GTP-bound ON and GDP-bound OFF state conformations of KRASG12C, leading to rapid and robust inhibition of KRASG12C activity. BBO-8520's ability to inhibit the ON state should provide optimal target coverage and address KRASG12C amplification and receptor tyrosine kinase activation - the two key mechanisms of adaptive resistance to current OFF state inhibitors. BBO-8520 drives substantial tumor growth inhibition in multiple preclinical models, even after emergence of resistance to sotorasib, an FDA approved OFF state inhibitor of KRASG12C.

07:25 EST Idaho Strategic expects continuation of recent production profile in 2024 - Idaho Strategic Resources providesits 2023 year in review via a President's Letter to Stakeholders, which read in part, "2023 was an exciting year for the Company on all fronts. Perhaps the biggest and most obvious change has been the Company's shift to profitability, which began in the fourth quarter of 2022 and has continued throughout the three reported quarters of 2023. Coinciding with the Company's increased revenue and profitability, I witnessed an extreme increase in ownership mentality amongst our team members at all levels of the organization. With an almost battlefield-like cohesiveness, the cooperation in our team is a trait rarely seen in business these days. It is very rewarding to see some of the seeds planted long ago that are now bearing fruit. Achieving profitability while building exploration upside is a goal that we have had since we began mining operations and it is only one differentiating factor that sets us apart from much of our junior mining peers...We anticipated and are cognizant of the long-term cycles that have reversed and while we may all be traversing the same seas, not all of us are in the same boat. Looking ahead to 2024, with all the caveats in place that are necessary for a junior producing mining company, I expect a continuation of the recent production profile of the Company as we look to maintain profitability. I also expect that 2024 will be another year where we are reinvesting our profits and cash flow - specifically into increased exploration of both the greater Murray Gold Belt District and our rare earth elements landholdings. From a macro perspective, we are positioned in a recognized store of value to help withstand and possibly benefit from both a devaluation of the U.S. Dollar and its lessening status as the World's reserve currency. Additionally, increased tensions with the U.S.' global adversaries and an increasing importance of securing domestic sources for minerals necessary for decarbonization and national security will make for a challenging year for our country and an interesting and potentially transformational 2024 for Idaho Strategic."

07:20 EST Phoenix's EdisonFuture plans to accept bitcoin payments - Phoenix Motor announced that its EdisonFuture subsidiary plans to accept Bitcoin as a payment option for its customers to pay for EdisonFuture brand electric pick-up trucks and delivery vans, once those products become available in the market. The company conducted market research and discovered that there was a growing interest around bitcoin which was accelerated by the coronavirus pandemic and complex geopolitics. This informed our decision to allow customers to pay for our products and services using bitcoin, and to better meet the growing demand for Web 3 and Artificial Intelligence in the near future.

07:18 EST Poet Technologies announces ZKTel as customer, collaborator - POET Technologies announced that Shaoxing ZKTel Equipment is one of the lead customers for POET's 100G optical engines. POET and ZKTel have been collaborating to develop a 100G CWDM4 optical transceiver module using POET optical engines supplied by POET's joint venture company, Super Photonics Xiamen. Each module contains a 100G CWDM4 transmit and a receive engine with monolithically integrated MUX and DMUX, directly modulated lasers, and high-speed photodiodes. POET developed the product to suit ZKTel's desired designs, demonstrating the flexibility of the optical interposer technology. "We have been working with ZKTel for more than a year and are pleased to announce a design win for POET with another module supplier that will go into production in 2024," said Dr. Suresh Venkatesan, POET's Chairman and CEO. "ZKTel is a highly respected and significant player in the China datacom industry and to collaborate with them through SPX is further validation of POET's commercial and technical strategy. ZKTel has a robust product portfolio and an expansive number of end users. Through this collaboration, POET and SPX have a roadmap with ZKTel that goes beyond the initial 100G CWDM optical engine sales."

07:17 EST Acreage Holdings enters New York AU market with first produce sale - Acreage announced it has launched Adult-Use, AU, operations in New York. "We are tremendously proud to officially become an adult-use wholesale distributor in New York," said Dennis Curran, Chief Executive Officer and Chairman of Acreage. "As a New York-headquartered company and long-time medical operator in the state, we have been anxiously awaiting the launch of our adult-use operations here. We believe there is immense growth potential in the Empire State, with it expected to become one of the largest cannabis markets in the country, representing an incredible opportunity for us to dramatically increase our total addressable consumer base. We have built strong relationships in New York and are well prepared for this long-anticipated AU launch, with our team having identified key partners for sales. For years, our high-quality products have only been available to medical-use patients, and we are excited for adult-use consumers to now learn why so many patients choose The Botanist."

07:15 EST Microbix Biosystems sells over C$1M of QAPs to lab PT, EQA services provider - Microbix Biosystems has sold and shipped over C$1 Million of its quality assessment products to a leading agency that provides clinical laboratory accreditation services. This is Microbix's largest-ever individual shipment to a lab proficiency-testing and external quality assessment services provider. The orders were for Microbix QAPs, in both the traditional liquid-vials and formatted onto Copan FLOQSwabs, to support proficiency programs covering numerous infectious diseases across multiple disease categories. The QAPs provided included those to support antigen and molecular tests. They will be used to help validate accuracy of testing on a wide range of test systems - ranging from high-throughput automated instruments to lower volume point-of-care and lab-developed tests. These sales were realized in the fourth quarter of calendar 2023. As with the over C$1 Million set of QAPs purchase orders from a multinational test-maker announced in late September, this PT/EQA-oriented set of P.Os. was nearly equivalent to a full year's worth of QAPs sales from 2020 and is indicative of Microbix beginning to realize its targeted sales growth for this segment of its business. The unit number of QAPs shipped under this set of P.Os. is in the tens of thousands and Microbix expects ongoing sales to this longtime PT/EQA customer

07:12 EST Kelly Services completes sale of European staffing business to Gi Group - Kell has completed the sale of its European staffing business to Gi Group Holdings S.P.A.. Kelly previously announced on November 2, 2023, that it had entered into a definitive agreement to sell the business to Gi. Kelly received cash proceeds of EUR 100 million upon closing the transaction. Additional proceeds from an earnout provision based on a multiple of an adjusted 2023 EBITDA measure would be payable in the second quarter of 2024 if achieved. With the sale of Kelly's European staffing business, the company's operating model comprises four reportable segments focused on global MSP and RPO solutions, and North American specialty outcome-based and staffing services. The segments include Professional & Industrial; Science, Engineering & Technology; Education; and Outsourcing & Consulting Group. The company retains its MSP, RPO, and functional service provider business, maintaining a global capability in these businesses in the North America, Asia Pacific, and Europe, Middle East, and Africa regions. The sale also accelerates the company's efforts to significantly improve its EBITDA margin through its ongoing business transformation initiative, contributing approximately 30 basis points of favorable impact on a pro forma, full year 2023 basis. By combining this impact with the benefit of a full year of expected transformation-related savings and current top-line expectations, the company would expect to achieve a normalized, adjusted EBITDA margin in the range of 3.3% to 3.5%.

07:11 EST Nano Labs announces update to holders of ADRs - Nano Labs announced that Citibank N.A., the depositary of the company's American depositary receipts, distributed to all holders and beneficial owners of the company's ADRs a notification on December 29, 2023 regarding the amendment to the deposit agreement, dated December 19, 2023, as amended, by and among the company, the Depositary, and all holders and beneficial owners of the ADRs, and the termination of ADR facility for the company's American depositary shares. The effective date of the termination of the Deposit Agreement will be February 1, 2024.

07:09 EST SEALSQ Corp. to launch cryptocurrency protocol SEALCOIN - SEALSQ will unveil its revolutionary cryptocurrency protocol, SEALCOIN, during the Davos roundtable on Space IoT and Cybersecurity. This pioneering event aims to address the critical aspects of cybersecurity in the era of Space IoT. SEALCOIN is designed as a solution for the emerging Machine-to-Machine economy, facilitating seamless data and currency exchanges among billions of internet-connected devices. This innovative protocol enables IoT structures from various companies to autonomously interact and access a wide range of services, transcending conventional currency exchange to encompass a complex network of IoT-enabled transactions and services.

07:08 EST Hepsiburada announces new CFO Koseolu takes office - D-MARKET Electronic Services & Trading, referred to herein as "Hepsiburada," announced that M. Seckin Koseolu has officially taken on the role of the Company's Chief Financial Officer, CFO, effective January 1, 2024. As previously announced on August 18, 2023, former CFO, Oz, will continue to hold his current board member positions in certain subsidiaries of the Company.

07:07 EST Nemaura Medical decides to accept Nasdaq determination to delist - Nemaura Medical is providing an update regarding recent decisions that will impact Nemaura Medical's listing status on The Nasdaq Capital Market and our broader strategic direction. The company said, "After thorough analysis, Nemaura Medical's Board of Directors and management team have made the strategic decision to accept Nasdaq's determination to delist Nemaura Medical and move to the OTC Markets. This decision arises from a careful consideration of several factors, including challenges outside of our control that have led to a significant attrition of the share price. In light of these circumstances, maintaining our Nasdaq listing would necessitate a substantial dilution of approximately 90%, a move we believe would not serve the best interests of our valued shareholders. The transition to the OTC Markets will provide operational flexibility, reduced compliance costs, and the ability to focus on long-term growth without the immediate pressures associated with maintaining a Nasdaq listing. Committed to creating shareholder value, we are actively pursuing strategic partnerships critical to driving Nemaura Medical's growth. We believe these partnerships will play a key role in securing the necessary funding to propel innovation, expand market presence, and enhance our overall competitiveness. We understand that this decision may raise questions and concerns. We want to assure shareholders that we remain committed to open and transparent communication. We value shareholder trust and support and are dedicated to keeping shareholders informed throughout this transition. As we navigate this new phase, regular updates on our progress, strategic partnerships, and any material developments impacting shareholders will be provided. Additionally, in the near-term, we will continue to file annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K with the SEC. Please feel free to reach out to our Investor Relations team via emailith any questions or if further clarification is needed. Thank you for your continued trust and confidence in Nemaura Medical. Together, we look forward to shaping a successful future."

07:06 EST Chemomab Therapeutics completes enrollment in Phase 2 trial of CM-101 - Chemomab Therapeutics announced early completion of patient enrollment in its Phase 2 clinical trial assessing CM-101 as a treatment for primary sclerosing cholangitis. The company also announced that it expects to report topline data from the PSC clinical trial by midyear 2024, rather than in the second half of 2024 as previously projected.

07:05 EST Bruker acquires electron microscopy company Nion, no terms - Bruker announced that it has acquired Nion, a privately-held company that develops and manufactures innovative high-end scanning transmission electron microscopes or STEM . Nion was the first company to introduce aberration correction for STEM instruments with ultra-high stability for highest resolution images, and Nion is the world leader in ultra-high energy and spatial resolution electron energy-loss spectroscopy or EELS. This acquisition enhances Bruker's product offerings and technology portfolio in materials science research and provides the technology base for applications in electron diffraction crystallography. In 2023, Nion had approximately $8M in revenue. Financial details of the transaction were not disclosed. Located in Kirkland, WA, USA, Nion was founded in 1997 by Dr. Ondrej Krivanek and Dr. Niklas Dellby. Under their leadership, Nion developed into a premier provider for high-end STEMs for researchers in materials science research worldwide.

07:05 EST Athira Pharma completes enrollment of Phase 2/3 LIFT-AD trial of fosgonimeton - Athira Pharma announced completion of enrollment in the Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer's disease. "The successful completion of enrollment in LIFT-AD marks an important milestone for Athira and enables the topline data readout in the second half of 2024," said Mark Litton, Ph.D., President and Chief Executive Officer of Athira. "We believe LIFT-AD has the potential to meet the study's primary endpoint based on the unblinded interim efficacy and futility analysis performed by an independent committee on the first 100 patients who completed the trial. This interim analysis gives us confidence in a potentially positive outcome for LIFT-AD, as stringent evaluation criteria were applied based on validated and clinically meaningful cognitive and functional outcomes.

07:04 EST Entrada Therapeutics promotes Dowden to President - Entrada Therapeutics announced that Nathan Dowden, current Chief Operating Officer of Entrada Therapeutics, has been promoted to President and Chief Operating Officer, effective as of January 1, 2024. Nate joined Entrada in 2019 and has 30 years of strategy, investment, and operational experience in the healthcare sector.

07:02 EST Invivyd submits request for EUA to U.S. FDA for VYD222 - Invivyd announced that it has requested Emergency Use Authorization, EUA, from the U.S. Food and Drug Administration, FDA, for VYD222, a broadly neutralizing, half-life extended monoclonal antibody candidate, for the pre-exposure prevention of COVID-19 in immunocompromised adults and adolescents. The EUA submission was based on positive initial results from the CANOPY Phase 3 pivotal clinical trial of VYD222, as well as ongoing in vitro neutralization activity against relevant variants such as JN.1. "We are tremendously pleased by the fact that VYD222 continues to demonstrate in vitro neutralization activity against the latest dominant variant, JN.1, as well as other prevalent SARS-CoV-2 strains," said Dave Hering, Chief Executive Officer of Invivyd. "We believe that the demonstrated durability of VYD222 is reflective of our strategy to select antibody candidates that target conserved epitopes to achieve our stated goal of keeping pace with viral evolution."

07:02 EST Griid Infrastructure receives commencement of delisting notice from NYSE - GRIID Infrastructure announces that, following the Company's notifying the NYSE American of the Company's intention to voluntarily delist from the Exchange, as previously disclosed in the Current Report on Form 8-K filed on January 2, 2024 with the United States Securities and Exchange Commission, the Company received a letter from the on January 2, 2024 stating that the staff of the Exchange has determined to commence proceedings to delist the Company's Common Stock, Units and Redeemable Warrants pursuant to Section 119(f) of the NYSE American Company Guide because the Company consummated a business combination transaction without the required authorization from the Exchange. At this time, the Securities have been suspended from trading on the Exchange and will not continue to trade on the Exchange. The Company has a right to a review of the delisting determination by a Committee of the Board of Directors of the Exchange, provided a written request for such review is requested no later than January 9, 2024. Consistent with its notification of the Exchange regarding its intention to voluntarily delist from the Exchange, the Company has notified the Exchange that it does not intend to make such a request.

06:50 EST Suncor reports upstream production of 808,000 barrels per day in Q4 - Suncor provided an operational update for the fourth quarter of 2023, highlighting upstream production of 808,000 barrels per day, or bbls/d, which it calls "the second highest quarter in the company's history." The fourth quarter performance results in an annual average upstream production of 746,000 bbls/d, in line with Suncor's corporate guidance provided in November 2022. Suncor's net synthetic crude oil production was 476,000 bbls/d and net non-upgraded bitumen production was 282,000 bbls/d; resulting in total Oil Sands production of 758,000 bbls/d for the quarter. Total production from Exploration & Production was 50,000 bbls/d during the fourth quarter and includes production from the ongoing ramp up of Terra Nova. "I am very proud of the Suncor team for ensuring we delivered on our commitments. Not only did we meet the annual production guidance set a year ago, but December was also Suncor's best month ever with upstream production averaging over 900,000 bbls/d. This is a tangible example that when we set a commitment, we will be laser focused on meeting it," said Rich Kruger, President and Chief Executive Officer.

06:33 EST Affimed to sell AbCheck to Ampersand Biomedicines for $6M - Affimed announced that it has reached a definitive agreement to sell its wholly-owned subsidiary, AbCheck s.r.o., to Ampersand Biomedicines. Under the terms of the agreement, Ampersand Biomedicines will acquire AbCheck for a purchase price of $6M consisting of $5M in cash to be paid in two tranches, and $1M in Ampersand common stock, subject to certain adjustments and a holdback. Affimed is also entitled to receive milestone payments from a pre-existing AbCheck partnership.

06:07 EST TDCX receives proposal from CEO to acquire remaining Class A ordinary shares - TDCX announced that its board of directors has received a preliminary non-binding proposal letter dated January 2, 2024, from Laurent Junique, Founder, Executive Chairman, Director, CEO, and ultimate beneficial owner of the company, to acquire all of the outstanding ordinary shares of the company, including the Class A ordinary shares represented by the American Depositary Shares of the company that are not already held by the Founder for a proposed purchase price of $6.60 per Ordinary Share or ADS in cash. The company has formed a special committee of the Board, comprised solely of independent and disinterested directors, to consider the Proposal Letter and the Proposed Transaction and make recommendation to the Board. The Board expects that the special committee will retain independent legal and financial advisors to assist in the review of the Proposed Transaction. The company cautions that the Board has just received the Proposal Letter and has not made any decisions with respect to the Proposal Letter and the Proposed Transaction. There can be no assurance that the Founder will make any definitive offer to the company, that any definitive agreement relating to the Proposal Letter will be entered into between the company and the Founder, or that the Proposed Transaction or any other similar transaction will be approved or consummated. The company does not undertake any obligation to provide any updates with respect to this or any other transaction, except as required under applicable law.

06:01 EST Disney, ValueAct Capital enter information-sharing arrangement - The Walt Disney Company and ValueAct Capital Management, L.P. have entered into a confidentiality agreement that enables the company to provide information to the investment firm and consult with ValueAct on strategic matters, including through meetings with the Disney Board and management. ValueAct has extensive experience investing in media and technology companies navigating significant business transformations, including Spotify, The New York Times, 21st Century Fox, Nintendo, Microsoft, Adobe and Salesforce. "ValueAct Capital has a track record of collaboration and cooperation with the companies it invests in, and its Co-CEO Mason Morfit has been very constructive in the conversations we've had over the past year. We welcome their input as long-term shareholders," said Robert A. Iger, Disney's CEO. "Disney is the world's leading entertainment company. It has the best intellectual property, sports brand and parks & experiences assets in the industry. As legacy technologies transition to digital platforms, we believe Disney can lead the media industry forward. We could not be more excited to partner with Bob and the Board to help create long-term sustainable shareholder value," said Mason Morfit, ValueAct Capital Co-CEO and Chief Investment Officer. ValueAct has confirmed it will support the Disney Board of Directors' recommended slate of nominees for election to the Board at the 2024 Annual Meeting.

05:36 EST GSI Technology selected by Afwerx for $1.1M SBIR Direct-to-Phase II contract - GSI Technology announced it has been selected by Afwerx for an SBIR Direct-to-Phase II contract in the amount of $1.1M to demonstrate high-data computation use cases leveraging the distinct compute in-memory architecture of its next-generation Associative Processing Unit-2, or APU2. GSI will create specialized algorithms for the U.S. Air Force Research Laboratory, or AFRL, to leverage the compute-in-memory architecture of the Gemini APU. This chip is designed for various AI applications to tackle key challenges in the Department of the Air Force, or DAF, including in-aircraft search and rescue, object detection, moving target indication, change detection, and SSIM in GPS-absent situations. GSI will also develop algorithms using data from the United States Space Force, or USSF, to showcase the performance benefits of its compute-in-memory APU2 integrated circuit, or IC.

05:10 EST Tencent Music, Universal Music Group extend multi-year strategic licensing pact - Tencent Music (TME) and Universal Music Group (UMGNF) announced the renewal of a multi-year strategic licensing agreement, fortifying their shared commitment to creating value for artists and exceptional experiences for music lovers. Under the agreement, TME continues to have access to UMG's music catalogue for QQ Music, Kugou Music, Kuwo Music, and WeSing. The partnership includes music streaming in Dolby Atmos and high-definition formats.